- Home
- Product Information
- Indications
- Administration
- In Vitro Activity and Mechanism of Action
- Clinical Efficacy
- Community Acquired Pneumonia
- Acute Exacerbation of Chronic Bronchitis
- Acute Bacterial Sinusitis
- Mild to Moderate Pelvic Inflammatory Disease
- Complicated Skin and Skin Structure Infections
- Complicated Intra-Abdominal Infections
- Safety
- FAQs
- Disease Area Information
Avelox® Clinical Efficacy
Clinical study data for Avelox® (moxifloxacin) in each of its licensed indications can be found by following the appropriate links below:
- Community Acquired Pneumonia (CAP)
- Acute Exacerbation of Chronic Bronchitis (AECB)
- Acute Bacterial Sinusitis (ABS)
- Mild to Moderate Pelvic Inflammatory Disease (PID)
- Complicated Skin and Skin Structure Infections (cSSSI)
- Complicated Intra-Abdominal Infections (cIAI)
For further information on using Avelox® in the management of bacterial infections, please consult your local country specific prescribing information.
